MedTrace Logo

Single Dose of Tranexamic Acid and Blood Loss, in Elderly Patients With Hip Fracture

NCT03251469 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-08-16

No results posted yet for this study

Summary

The aim of this study is to investigate the hypothesis that single dose of tranexamic acid (TXA) preoperatively will lower blood loss and transfusion rate in elderly patients with hip fractures (intertrochanteric or Subcapital), that will be treated with intramedullary nailing and cemented hemiarthroplasty respectively. After application of inclusion and exclusion criteria, patients will be randomized in two groups. Group 1 will include patients that receive preoperatively single dose of TXA (15mg/kg) and Group 2 will include patients that receive normal saline (control group).

Conditions

  • Blood Loss, Surgical
  • Hip Fractures
  • Complication, Postoperative

Interventions

DRUG

Tranexamic Acid 15mg/kg , iv, Single Dose

Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose

DRUG

Normal Saline, 100mg, iv, Singe dose

Normal Saline, 100mg, administered intravenously, preoperatively in single dose

Sponsors & Collaborators

  • National and Kapodistrian University of Athens

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2017-12-31
Completion
2018-02-28

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03251469 on ClinicalTrials.gov